Archive · CNBC Markets
Eli Lilly is about to report earnings. Here's what to expect
Eli Lilly is slated to report third-quarter earnings and revenue, which will likely be fueled by its obesity drug Zepbound and diabetes counterpart Mounjaro.
ZAZTEK archives the headline, summary and publication date so the story stays findable. The full article remains the publisher's. Read it at CNBC Markets →